Metformin in Gestational Diabetes

Phase 4

Recruiting

• Conditions: Gestational diabetes; Metabolic and Endocrine - Diabetes; Reproductive Health and Childbirth - Fetal medicine and complications of pregnancy

• Registration Number: ACTRN12605000266662
• Lead Sponsor: HRC

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-02
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 750

Inclusion Criteria

22-33 weeks' gestation, singleton pregnancy, capillary glucose levels requiring additional treatment.

Exclusion Criteria

Diabetes diagnosed pregnancy, gestational hypertension, pre-eclampsia of fetal growth restriction at study entry, fetal congenital anomaly, maternal medical conditon posing contra-indication to metformin.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Composite of neonatal morbidity including hypoglycaemia, respiratory distress, prematurity, phototherapy birth trauma, and low Apgar.[At 5 minutes]

Secondary Outcome Measures

Name	Time	Method
Maternal glycaemia control[];Neonatal anthropometry[];Cord blood measures of adipoinsular axis[];Maternal hypertensive complications and postpartum GTT results[];Acceptability of treatments.[]